Virus C hepatitis and type 2 diabetes: A cohort study in Southern Italy

L. Montenegro, A. De Michina, G. Misciagna, V. Guerra, A. Di Leo

Research output: Contribution to journalArticle

Abstract

OBJECTIVES:The relationship between hepatitis C virus (HCV) infection and type 2 diabetes mellitus (DM 2) is still uncertain. The objective of this study was to evaluat. The association between HCV infection, measured as positivity to anti-HCV antibodies, an. The incidence of DM 2 in a cohort of subjects sampled fro. The general population and followed up for 20 years.METHODS:At baseline. The cohort consisted of a random sample of 2,472 subjects (72% response rate, age range 30-69 years) fro. The electoral register of a town in Southern Italy. The cohort subjects were examined three times: in 1985 (M1), in 1992 (M2), and in 2005 (M3). At M1, M2, and M3, each participant filled in a questionnaire and had a blood sample taken to measure blood glucose and other serum variables including glutamic pyruvic alanine aminotransferase (ALT). Anti-HCV antibodies were analyzed with standard techniques at M1 and M2. Diabetes type 2 diagnosis was a history of diabetes and/or serum glucose ≥126 mg/dl and/or treatment with insulin or hypoglycemic drugs. Logistic regression was used for multivariable data analysis.RESULTS:Diabetes prevalence was higher in subjects with positive anti-HCV antibodies at M1 and M2, and diabetes incidence was higher in subjects with baseline positive anti-HCV antibodies at M1-M2 and lower at M2-M3. In multivariable models, controlling for gender, age, and body mass index (BMI), there was no association between incident cases of diabetes and positive anti-HCV antibodies at baseline, either at M1-M2 (odds ratio (OR) 0.73, 95% confidence interval (CI) 0.43-1.22) or at M2-M3 (0.65, 0.41-1.04). HCV was associated with DM 2 only in subjects with elevated ALT (OR 0.58, 95% CI 0.31-1.08, if ALT normal; OR 1.47, 95% CI 1-2.16, if ALT elevated, controlling for age, gender, and BMI).CONCLUSIONS:Our findings, in a cohort study at population level, support an association betwee. The presence of anti-HCV antibodies at baseline and a higher incidence of type 2 diabetes i. The following 20 years only in subjects with elevated ALT.

Original languageEnglish
Pages (from-to)1108-1111
Number of pages4
JournalAmerican Journal of Gastroenterology
Volume108
Issue number7
DOIs
Publication statusPublished - Jul 2013

Fingerprint

Hepatitis C Antibodies
Hepacivirus
Type 2 Diabetes Mellitus
Italy
Alanine Transaminase
Cohort Studies
Odds Ratio
Virus Diseases
Confidence Intervals
Incidence
Body Mass Index
Serum
Type 1 Diabetes Mellitus
Hypoglycemic Agents
Population
Blood Glucose
Logistic Models
Insulin
Glucose

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Virus C hepatitis and type 2 diabetes : A cohort study in Southern Italy. / Montenegro, L.; De Michina, A.; Misciagna, G.; Guerra, V.; Di Leo, A.

In: American Journal of Gastroenterology, Vol. 108, No. 7, 07.2013, p. 1108-1111.

Research output: Contribution to journalArticle

Montenegro, L. ; De Michina, A. ; Misciagna, G. ; Guerra, V. ; Di Leo, A. / Virus C hepatitis and type 2 diabetes : A cohort study in Southern Italy. In: American Journal of Gastroenterology. 2013 ; Vol. 108, No. 7. pp. 1108-1111.
@article{a17864772629433daf51757f341439e8,
title = "Virus C hepatitis and type 2 diabetes: A cohort study in Southern Italy",
abstract = "OBJECTIVES:The relationship between hepatitis C virus (HCV) infection and type 2 diabetes mellitus (DM 2) is still uncertain. The objective of this study was to evaluat. The association between HCV infection, measured as positivity to anti-HCV antibodies, an. The incidence of DM 2 in a cohort of subjects sampled fro. The general population and followed up for 20 years.METHODS:At baseline. The cohort consisted of a random sample of 2,472 subjects (72{\%} response rate, age range 30-69 years) fro. The electoral register of a town in Southern Italy. The cohort subjects were examined three times: in 1985 (M1), in 1992 (M2), and in 2005 (M3). At M1, M2, and M3, each participant filled in a questionnaire and had a blood sample taken to measure blood glucose and other serum variables including glutamic pyruvic alanine aminotransferase (ALT). Anti-HCV antibodies were analyzed with standard techniques at M1 and M2. Diabetes type 2 diagnosis was a history of diabetes and/or serum glucose ≥126 mg/dl and/or treatment with insulin or hypoglycemic drugs. Logistic regression was used for multivariable data analysis.RESULTS:Diabetes prevalence was higher in subjects with positive anti-HCV antibodies at M1 and M2, and diabetes incidence was higher in subjects with baseline positive anti-HCV antibodies at M1-M2 and lower at M2-M3. In multivariable models, controlling for gender, age, and body mass index (BMI), there was no association between incident cases of diabetes and positive anti-HCV antibodies at baseline, either at M1-M2 (odds ratio (OR) 0.73, 95{\%} confidence interval (CI) 0.43-1.22) or at M2-M3 (0.65, 0.41-1.04). HCV was associated with DM 2 only in subjects with elevated ALT (OR 0.58, 95{\%} CI 0.31-1.08, if ALT normal; OR 1.47, 95{\%} CI 1-2.16, if ALT elevated, controlling for age, gender, and BMI).CONCLUSIONS:Our findings, in a cohort study at population level, support an association betwee. The presence of anti-HCV antibodies at baseline and a higher incidence of type 2 diabetes i. The following 20 years only in subjects with elevated ALT.",
author = "L. Montenegro and {De Michina}, A. and G. Misciagna and V. Guerra and {Di Leo}, A.",
year = "2013",
month = "7",
doi = "10.1038/ajg.2013.90",
language = "English",
volume = "108",
pages = "1108--1111",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Virus C hepatitis and type 2 diabetes

T2 - A cohort study in Southern Italy

AU - Montenegro, L.

AU - De Michina, A.

AU - Misciagna, G.

AU - Guerra, V.

AU - Di Leo, A.

PY - 2013/7

Y1 - 2013/7

N2 - OBJECTIVES:The relationship between hepatitis C virus (HCV) infection and type 2 diabetes mellitus (DM 2) is still uncertain. The objective of this study was to evaluat. The association between HCV infection, measured as positivity to anti-HCV antibodies, an. The incidence of DM 2 in a cohort of subjects sampled fro. The general population and followed up for 20 years.METHODS:At baseline. The cohort consisted of a random sample of 2,472 subjects (72% response rate, age range 30-69 years) fro. The electoral register of a town in Southern Italy. The cohort subjects were examined three times: in 1985 (M1), in 1992 (M2), and in 2005 (M3). At M1, M2, and M3, each participant filled in a questionnaire and had a blood sample taken to measure blood glucose and other serum variables including glutamic pyruvic alanine aminotransferase (ALT). Anti-HCV antibodies were analyzed with standard techniques at M1 and M2. Diabetes type 2 diagnosis was a history of diabetes and/or serum glucose ≥126 mg/dl and/or treatment with insulin or hypoglycemic drugs. Logistic regression was used for multivariable data analysis.RESULTS:Diabetes prevalence was higher in subjects with positive anti-HCV antibodies at M1 and M2, and diabetes incidence was higher in subjects with baseline positive anti-HCV antibodies at M1-M2 and lower at M2-M3. In multivariable models, controlling for gender, age, and body mass index (BMI), there was no association between incident cases of diabetes and positive anti-HCV antibodies at baseline, either at M1-M2 (odds ratio (OR) 0.73, 95% confidence interval (CI) 0.43-1.22) or at M2-M3 (0.65, 0.41-1.04). HCV was associated with DM 2 only in subjects with elevated ALT (OR 0.58, 95% CI 0.31-1.08, if ALT normal; OR 1.47, 95% CI 1-2.16, if ALT elevated, controlling for age, gender, and BMI).CONCLUSIONS:Our findings, in a cohort study at population level, support an association betwee. The presence of anti-HCV antibodies at baseline and a higher incidence of type 2 diabetes i. The following 20 years only in subjects with elevated ALT.

AB - OBJECTIVES:The relationship between hepatitis C virus (HCV) infection and type 2 diabetes mellitus (DM 2) is still uncertain. The objective of this study was to evaluat. The association between HCV infection, measured as positivity to anti-HCV antibodies, an. The incidence of DM 2 in a cohort of subjects sampled fro. The general population and followed up for 20 years.METHODS:At baseline. The cohort consisted of a random sample of 2,472 subjects (72% response rate, age range 30-69 years) fro. The electoral register of a town in Southern Italy. The cohort subjects were examined three times: in 1985 (M1), in 1992 (M2), and in 2005 (M3). At M1, M2, and M3, each participant filled in a questionnaire and had a blood sample taken to measure blood glucose and other serum variables including glutamic pyruvic alanine aminotransferase (ALT). Anti-HCV antibodies were analyzed with standard techniques at M1 and M2. Diabetes type 2 diagnosis was a history of diabetes and/or serum glucose ≥126 mg/dl and/or treatment with insulin or hypoglycemic drugs. Logistic regression was used for multivariable data analysis.RESULTS:Diabetes prevalence was higher in subjects with positive anti-HCV antibodies at M1 and M2, and diabetes incidence was higher in subjects with baseline positive anti-HCV antibodies at M1-M2 and lower at M2-M3. In multivariable models, controlling for gender, age, and body mass index (BMI), there was no association between incident cases of diabetes and positive anti-HCV antibodies at baseline, either at M1-M2 (odds ratio (OR) 0.73, 95% confidence interval (CI) 0.43-1.22) or at M2-M3 (0.65, 0.41-1.04). HCV was associated with DM 2 only in subjects with elevated ALT (OR 0.58, 95% CI 0.31-1.08, if ALT normal; OR 1.47, 95% CI 1-2.16, if ALT elevated, controlling for age, gender, and BMI).CONCLUSIONS:Our findings, in a cohort study at population level, support an association betwee. The presence of anti-HCV antibodies at baseline and a higher incidence of type 2 diabetes i. The following 20 years only in subjects with elevated ALT.

UR - http://www.scopus.com/inward/record.url?scp=84880222037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880222037&partnerID=8YFLogxK

U2 - 10.1038/ajg.2013.90

DO - 10.1038/ajg.2013.90

M3 - Article

C2 - 23567360

AN - SCOPUS:84880222037

VL - 108

SP - 1108

EP - 1111

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 7

ER -